13-HODE
metabolite13-HODE, an oxidized linoleic acid metabolite, suppresses platelet aggregation and protects against thrombosis in Type 1 MI.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleOxidized PUFA metabolite inhibiting platelet aggregation.
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I38
C — confounder / Type-II36
A — assay feasibility42
E — evidence strength17
T1DI (composite)4
Specificity differential (R−C)+2.2
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Acute coronary syndrome remodels the antiplatelet aggregation properties of HDL particle subclasses.Journal of thrombosis and haemostasis : JTH · 2018 · PMID 29543379 · doi